Replies to post #153962 on Rivulet Media Inc (fka RIVU)

[ADVFN_franknstein]

Each news release lists RGBP as a controlled subsidiary of Bio Matrix

This is correct for SEC filings like the 8-k, 10-Q ...
But nor for press releases !
Starting with the press release June 12, 2015 BMSN is no longer mentioned in Regens PR's.

About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.

[stervc]

Important from BMSN 8-K filed on 12/17/2015...

Before I talk about the inter-institutional agreement that has been confirmed with the National Center for Advancing Translational Sciences (“NCATS”), which is a component of the National Institutes of Health (“NIH”), there are some key pieces regarding this 8-K that must be considered.

This piece is positively important from the Bio Matrix Scientific Group, Inc. (BMSN) 8-K that was filed with the SEC on 12/17/2015 because it confirms that regardless to what was previously considered as their portion of ownership of Regen Biopharma, Inc. (RGBP), as of 12/17/2015… in my opinion… BMSN now owns at least a 51% Controlling Interest in RGBP. Based on what was recently filed in the BMSN 8-K, such confirms that either shares have been recently moved over and/or issued into the name of BMSN or somehow shares have been re-organized to ensure that BMSN still has the ”51% controlling interest” in RGBP because it specifically stated such within the 8-K below:

http://ih.advfn.com/p.php?pid=nmona&article=69735995&symbol=BMSN
Regen is a controlled subsidiary of Bio Matrix Scientific Group, Inc. (BMSN)

Also important, per the BMSN 8-K that was filed with the SEC on 12/17/2015:

Item 1.01 Entry Into A Material Definitive Agreement

On December 15, 2015 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with the National Center for Advancing Translational Sciences (“NCATS”), which is a component of the National Institutes of Health (“NIH”), an agency of the U.S. Department of Health and Human Services, pursuant to the following terms and conditions:

Regen and NCATS shall collaborate to screen for small molecule compounds that activate or inhibit the orphan nuclear receptor, NR2F6 (“Research Project”).

NR2F6 orphan nuclear receptor cell lines will be provided by Regen.

NPC and LOPAC compound libraries will be used to screen this receptor at NCATS.

Inventions made in the course of the Research Project will be owned by the Party employing the inventor or inventors. Inventions that are invented jointly by employees of both Parties will be owned jointly.

The Parties, moreover, agree to enter into an inter-institutional agreement with respect to joint inventions, which shall authorize Regen to have primary control and responsibility for any patenting and commercialization activities and shall be negotiated in good faith based on the respective parties’ contributions to each Joint Invention.

The term of this Agreement is for 3 years from December 16, 2015. This Agreement may be extended as mutually agreed by the Parties. ...

Now I think it is important to get to know a little bit more about who they have entered into an inter-institutional agreement with… National Center for Advancing Translational Sciences (“NCATS”), which is a component of the National Institutes of Health (“NIH”), an agency of the U.S. Department of Health and Human Services:

https://ncats.nih.gov/


http://www.nih.gov/

https://www.linkedin.com/company/national-center-for-advancing-translational-science-ncats
National Center for Advancing Translational Sciences (NCATS)


National Center for Advancing Translational Sciences (“NCATS”), which is a component of the National Institutes of Health (“NIH”), an agency of the U.S. Department of Health and Human Services. To understand the magnitude of this relationship, below is the NIH Funding Report confirming over $21.9 Billion awarded to companies in funding for 2015:
https://report.nih.gov/award/index.cfm?ot=&fy=2015&state=&ic=&fm=&orgid=&distr=&rfa=&om=n&pid=

The Search criteria should look like this to be able to see this:

https://report.nih.gov/award/index.cfm?ot=&fy=2015&state=&ic=&fm=&orgid=&distr=&rfa=&om=n&pid=

After pulling it up, one can confirm the $21.9 Billion awarded to companies in funding for 2015 by exporting the data to an Excel spreadsheet as a given option to quickly add such up. This is huge because this is a ”government entity” that has been indicated within the BMSN 8-K that was recently filed with the SEC. If it wasn’t true, no way would such an entity allow their name to be publicly associated with BMSN unless they knew that what they are doing is very real with massive potential for gains and growth. This is why I believe it is a matter of ”when” will BMSN move and not a matter of ”if” with all that has been indicated.

Also, there is much more out there by Googling much about NCATS/NIH. Here is one Forbes article below to read to get an idea of the magnitude of what this relationship between BMSN and NCATS/NIH should mean moving forward as Penn Medicine is one of the world’s leading academic medical centers which is also a $4.3 billion enterprise. The school is consistently among the nation’s top recipients of funding from the NIH with being awarded $392 million in the 2013 fiscal year:
http://custom.forbes.com/2015/12/11/philadelphia/

This is why I am expecting huge funding news. I think BMSN is in some very good hands.

https://ncats.nih.gov/files/NCATS-factsheet.pdf




v/r
Sterling